BD’s Diabetes Division Is Unruffled By Continuous Monitoring, Inhaled Insulin
This article was originally published in The Gray Sheet
Executive Summary
BD remains confident in its traditional needle-and-test-strip-based diabetes management business despite the advent of continuous glucose monitoring and inhaled insulin delivery - technologies touted as less invasive, more user-friendly alternatives
You may also be interested in...
BD Exits Glucose Monitoring Market After Being “Eclipsed” By Competitors
Becton Dickinson is dropping out of the increasingly competitive blood glucose monitoring market, acknowledging that it has been too slow to innovate in a sector that generated about $105 mil. in BD sales for the 12 months ended Sept. 30
BD Exits Glucose Monitoring Market After Being “Eclipsed” By Competitors
Becton Dickinson is dropping out of the increasingly competitive blood glucose monitoring market, acknowledging that it has been too slow to innovate in a sector that generated about $105 mil. in BD sales for the 12 months ended Sept. 30
Medtronic Moves Closer To Closed-Loop Diabetes Care With Paradigm
Earlier-than-anticipated approval of its Paradigm real-time insulin pump and continuous glucose monitoring system again puts Medtronic one step ahead of the competition in moving toward "closed-loop" diabetes management, the company suggests